A Prospective Multicenter Open-Label Study of the Effectiveness of Epoetin Beta for Patients with Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Preliminary Result

被引：3

作者：

Chuncharunee, Suporn ^{[1
]}

Kanitsap, Nonglak ^{[2
]}

Suwanban, Tawatchai ^{[3
]}

Khuhapinant, Archrob ^{[4
]}

Uaprasert, Noppacharn ^{[5
]}

Chansung, Kanchana ^{[6
]}

Rattarittamrong, Ekarat ^{[7
]}

Wongkhantee, Somchai ^{[8
]}

Siritanaratanakul, Noppadol ^{[4
]}

Norasetthada, Lalita ^{[7
]}

Nakorn, Thanyaphong Na ^{[5
]}

Charnwiboonsri, Chadchai ^{[9
]}

机构：

[1] Mahidol Univ, Ramathibodi Hosp, Dept Internal Med, Bangkok, Thailand

[2] Thammasat Univ, Dept Internal Med, Pathum Thani, Thailand

[3] Rajavithi Hosp, Dept Internal Med, Bangkok, Thailand

[4] Mahidol Univ, Siriraj Hosp, Dept Med, Bangkok, Thailand

[5] Chulalongkorn Univ, Dept Med, Bangkok, Thailand

[6] Khon Kaen Univ, Dept Internal Med, Khon Kaen, Thailand

[7] Chiang Mai Univ, Dept Internal Med, Chiang Mai, Thailand

[8] Khonkaen Reg Hosp, Dept Internal Med, Khon Kaen, Thailand

[9] Roche Thailand Ltd, Med Dept, Bangkok, Thailand

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.5543.5543

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5543

引用

页数：4

共 50 条

[41] CLINICAL FACTORS PREDISPOSING TO ACHIEVEMENT OF RBC TRANSFUSION INDEPENDENCEIN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES) WITHOUT DEL(5q) IN MDS-005 STUDY [J].

Santini, V. ;

Li, J. Shiansong ;

Swern, A. S. ;

Almeida, A. ;

Giagounidis, A. ;

Fu, T. ;

Sanna, A. ;

Hoenekopp, A. ;

Beach, C. L. ;

Skikne, B. ;

Fenaux, P. .

HAEMATOLOGICA, 2015, 100 :3-4

[42] Anti-PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study. [J].

Wang, Jing ;

Li, Siqi ;

Jiang, Hao ;

Chang, Ying-Jun ;

Zhao, Xiao-Su ;

Jia, Jin-Song ;

Zhu, Xiao-Lu ;

Gong, Li-Zhong ;

Liu, Xiao-Hong ;

Yu, Wen-Jing ;

Huang, Xiao-Jun .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

[43] Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain:: A multicenter, open-label, uncontrolled, prospective, observational clinical study [J].

Muriel, C ;

Failde, I ;

Micó, JA ;

Neira, M ;

Sánchez-Magro, I .

CLINICAL THERAPEUTICS, 2005, 27 (04) :451-462

[44] Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) [J].

Assi, Rita ;

Kantarjian, Hagop M. ;

Daver, Naval G. ;

Garcia-Manero, Guillermo ;

Benton, Christopher B. ;

Thompson, Philip A. ;

Borthakur, Gautam ;

Kadia, Tapan M. ;

Alvarado, Yesid ;

Jabbour, Elias J. ;

Konopleva, Marina Y. ;

Takahashi, Koichi ;

Kornblau, Steven M. ;

DiNardo, Courtney D. ;

Estrov, Zeev E. ;

Flores, Wilmer ;

Basu, Sreyashi ;

Allison, James P. ;

Sharma, Padmanee ;

Pierce, Sherry A. ;

Pike, Allison ;

Cortes, Jorge E. ;

Ravandi, Farhad .

BLOOD, 2018, 132

[45] Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide [J].

Lyons, Roger M. ;

Larson, Richard A. ;

Kosmo, Michael A. ;

Gandhi, Sunil ;

Liu, Delong ;

Chernoff, Marc ;

Dreisbach, Luke ;

Matei, Carmen ;

Hu, Kuolong ;

Franklin, Janet L. ;

Berger, Dietmar .

BLOOD, 2009, 114 (22) :703-704

[46] MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS ERYTHROPOIETIN ON RBC TRANSFUSION INDEPENDENCE IN LENALIDOMIDE-TREATED PATIENTS WITH LOW OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITHOUT DEL(5Q) [J].

Santini, V. ;

Li, J. S. ;

Swern, A. S. ;

Almeida, A. ;

Giagounidis, A. ;

Fu, T. ;

Hoenekopp, A. ;

Beach, C. ;

Skikne, B. ;

Fenaux, P. .

HAEMATOLOGICA, 2015, 100 :69-69

[47] Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) [J].

C. Ola Landgren ;

Ajai Chari ;

Yael C. Cohen ;

Andrew Spencer ;

Peter Voorhees ;

Jane A. Estell ;

Irwindeep Sandhu ;

Matthew W. Jenner ;

Catherine Williams ;

Michele Cavo ;

Niels W. C. J. van de Donk ;

Meral Beksac ;

Philippe Moreau ;

Hartmut Goldschmidt ;

Steven Kuppens ;

Rajesh Bandekar ;

Pamela L. Clemens ;

Tobias Neff ;

Christoph Heuck ;

Ming Qi ;

Craig C. Hofmeister .

Leukemia, 2020, 34 :1840-1852

[48] Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) [J].

Landgren, C. Ola ;

Chari, Ajai ;

Cohen, Yael C. ;

Spencer, Andrew ;

Voorhees, Peter ;

Estell, Jane A. ;

Sandhu, Irwindeep ;

Jenner, Matthew W. ;

Williams, Catherine ;

Cavo, Michele ;

van de Donk, Niels W. C. J. ;

Beksac, Meral ;

Moreau, Philippe ;

Goldschmidt, Hartmut ;

Kuppens, Steven ;

Bandekar, Rajesh ;

Clemens, Pamela L. ;

Neff, Tobias ;

Heuck, Christoph ;

Qi, Ming ;

Hofmeister, Craig C. .

LEUKEMIA, 2020, 34 (07) :1840-1852

[49] A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial with Aripiprazole (BETA) [J].

Tandon, Rajiv ;

Marcus, Ronald N. ;

Stock, Elyse G. ;

Riera, Linda C. ;

Kostic, Dusan ;

Pans, Miranda ;

McQuade, Robert D. ;

Nyilas, Margaretta ;

Iwamoto, Taro ;

Crandall, David T. .

SCHIZOPHRENIA RESEARCH, 2006, 84 (01) :77-89

[50] Azacitidine pretreatment followed by non-myeloablative SCT in patients with high-risk myelodysplastic syndrome: Prospective, open label, multicenter, phase II trial [J].

Kim, H. ;

Jae-Sook, A. ;

Kim, Y. ;

Min, Y. H. ;

Kim, J. S. ;

Jang, J. H. ;

Jung, C. W. ;

Kim, I. H. ;

Yoon, H. J. ;

Lee, H. G. ;

Sohn, S. K. ;

Moon, J. H. ;

Kim, H. ;

Kim, Y. J. ;

Won, J. H. ;

Bang, S. M. ;

Chung, J. S. ;

Mun, Y. C. .

LEUKEMIA RESEARCH, 2013, 37 :S151-S151

← 1 2 3 4 5 →